@prefix this: . @prefix rdfs: . @prefix xsd: . @prefix sio: . @prefix ncit: . @prefix lld: . @prefix miriam-gene: . @prefix miriam-pubmed: . @prefix eco: . @prefix wi: . @prefix prov: . @prefix pav: . @prefix prv: . @prefix dcterms: . @prefix np: . @prefix dgn-np: . @prefix dgn-gda: . @prefix dgn-void: . dgn-np:NP81832.RArcQgyPFD6GULI0MrHJ55ZHlMkx49JnLyUQg5-IKd8yU130_head { this: np:hasAssertion dgn-np:NP81832.RArcQgyPFD6GULI0MrHJ55ZHlMkx49JnLyUQg5-IKd8yU130_assertion; np:hasProvenance dgn-np:NP81832.RArcQgyPFD6GULI0MrHJ55ZHlMkx49JnLyUQg5-IKd8yU130_provenance; np:hasPublicationInfo dgn-np:NP81832.RArcQgyPFD6GULI0MrHJ55ZHlMkx49JnLyUQg5-IKd8yU130_publicationInfo; a np:Nanopublication . dgn-np:NP81832.RArcQgyPFD6GULI0MrHJ55ZHlMkx49JnLyUQg5-IKd8yU130_assertion a np:Assertion . dgn-np:NP81832.RArcQgyPFD6GULI0MrHJ55ZHlMkx49JnLyUQg5-IKd8yU130_provenance a np:Provenance . dgn-np:NP81832.RArcQgyPFD6GULI0MrHJ55ZHlMkx49JnLyUQg5-IKd8yU130_publicationInfo a np:PublicationInfo . } dgn-np:NP81832.RArcQgyPFD6GULI0MrHJ55ZHlMkx49JnLyUQg5-IKd8yU130_assertion { miriam-gene:4524 a ncit:C16612 . lld:C0003873 a ncit:C7057 . dgn-gda:DGNd0ebc5b00b8171dce78465f6d9b3e828 sio:SIO_000628 miriam-gene:4524, lld:C0003873; a sio:SIO_001122 . } dgn-np:NP81832.RArcQgyPFD6GULI0MrHJ55ZHlMkx49JnLyUQg5-IKd8yU130_provenance { dgn-np:NP81832.RArcQgyPFD6GULI0MrHJ55ZHlMkx49JnLyUQg5-IKd8yU130_assertion dcterms:description "[The following variables were found to be the independent predictors of RA remission: male sex; young age; late-onset RA; short disease duration; nonsmoker; low baseline disease activity; mild functional impairment; low baseline radiographic damage; absence of rheumatoid factor and anti-citrullinated peptide; low serum level of acute-phase reactant, interleukin-2, and RANKL at baseline; MTHFR 677T alleles and 1298C alleles in the methotrexate (MTX)-treated patients; magnetization transfer ratio 2756A allele +/- either the SLC 19A180A allele or the TYMS 3R-del6 haplotype in the MTX plus sulfasalazine combination-treated patients; early treatment with nonbiologic disease-modifying antirheumatic drug (DMARD) combinations; the use of anti-tumor necrosis factor (anti-TNF); the concurrent use of DMARDs in anti-TNF-treated patients; and moderate or good response to treatments at the first 6 months.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en; wi:evidence dgn-void:source_evidence_literature; sio:SIO_000772 miriam-pubmed:20235210; prov:wasDerivedFrom dgn-void:gad-20150221; prov:wasGeneratedBy eco:ECO_0000203 . dgn-void:gad-20150221 pav:importedOn "2015-02-21"^^xsd:date . dgn-void:source_evidence_literature a eco:ECO_0000212; rdfs:comment "Gene-disease associations inferred from text-mining the literature."@en; rdfs:label "DisGeNET evidence - LITERATURE"@en . } dgn-np:NP81832.RArcQgyPFD6GULI0MrHJ55ZHlMkx49JnLyUQg5-IKd8yU130_publicationInfo { this: dcterms:created "2015-08-25T14:38:24+02:00"^^xsd:dateTime; dcterms:rights ; dcterms:rightsHolder dgn-void:IBIGroup; dcterms:subject sio:SIO_000983; prv:usedData dgn-void:disgenetv3.0rdf; pav:authoredBy , , , , ; pav:createdBy ; pav:version "v3.0.0.0" . dgn-void:disgenetv3.0rdf pav:version "v3.0.0" . }